AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Nivolumab (Primary) ; Dendritic cell vaccines
- Indications Glioma
- Focus Adverse reactions
- Acronyms AVERT
- 15 Dec 2017 Status changed to active, no longer recruiting.
- 28 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Sep 2018.
- 08 Feb 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018 as reported by ClinicalTrials.gov record.